文献速递糖尿病

美国24家医疗机构2型糖尿病初级保健患者慢性肾病检测现状

Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations.
PubMed 文献 · Diabetes Care · 2021-07-07

本研究分析513165名2型糖尿病成人电子健康记录,评估24家机构1164个临床站点中eGFR和uACR检测率。结果显示eGFR检测率中位数89.5%较高,但uACR检测率仅52.9%且机构间差异大,指南推荐的uACR检测可提高CKD检出。

要点

  • 1年内eGFR检测率中位数89.5%,uACR仅52.9%
  • uACR检测率在机构间10-90百分位44.7-63.3%,站点间13.3-75.4%
  • 检出白蛋白尿患病率15%,随uACR检测率线性增加

核心结论

  • eGFR检测率普遍高,但uACR检测率不达标且机构内外差异大。
  • 指南推荐的uACR检测应能提高CKD检出。

研究设计与样本

  • 分析513165名2型糖尿病成人电子健康记录,来自24家医疗机构1164个临床站点。
  • 评估截止2019年9月的1、2、3年内eGFR和uACR检测率。

主要发现

  • 1年机构中位检测率:eGFR和uACR双检51.6%,eGFR 89.5%,uACR 52.9%。
  • uACR检测率机构间10-90百分位44.7-63.3%,站点间13.3-75.4%。
  • 3年机构uACR检测率中位数73.7%。
  • 检出白蛋白尿(uACR≥30 mg/g)总体患病率15%。
  • 站点uACR检测率20%、50%、100%时,检出白蛋白尿患病率估计分别为6%、15%、30%。

关键数值与推荐

  • 白蛋白尿升高定义为uACR≥30 mg/g。
  • 指南推荐糖尿病患者至少每年检测eGFR和uACR。

临床怎么用

  • 应加强2型糖尿病患者的uACR年度检测。
  • 提高uACR检测率可增加CKD检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinical guidelines for people with diabetes recommend chronic kidney disease (CKD) testing at least annually using estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (uACR). We aimed to understand CKD testing among people with type 2 diabetes in the U.S. RESEARCH DESIGN AND METHODS: Electronic health record data were analyzed from 513,165 adults with type 2 diabetes receiving primary care from 24 health care organizations and 1,164 clinical practice sites. We assessed the percentage of patients with both one or more eGFRs and one or more uACRs and each test individually in the 1, 2, and 3 years ending September 2019 by health care organization and clinical practice site. Elevated albuminuria was defined as uACR ≥30 mg/g. RESULTS: The 1-year median testing rate across organizations was 51.6% for both uACR and eGFR, 89.5% for eGFR, and 52.9% for uACR. uACR testing varied (10th-90th percentile) from 44.7 to 63.3% across organizations and from 13.3 to 75.4% across sites. Over 3 years, the median testing rate for uACR across organizations was 73.7%. Overall, the prevalence of detected elevated albuminuria was 15%. The average prevalence of detected elevated albuminuria increased linearly with uACR testing rates at sites, with estimated prevalence of 6%, 15%, and 30% at uACR testing rates of 20%, 50%, and 100%, respectively. CONCLUSIONS: While eGFR testing rates are uniformly high among people with type 2 diabetes, testing rates for uACR are suboptimal and highly variable across and within the organizations examined. Guideline-recommended uACR testing should increase detection of CKD.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Stempniewicz N, Vassalotti JA, Cuddeback JK, et al. Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Diabetes Care. 2021. PMID: 34233925. doi:10.2337/dc20-2715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。